Efgartigimod
Phase 2Terminated 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome
Conditions
Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome
Trial Timeline
Jun 20, 2023 → Aug 15, 2024
NCT ID
NCT05918978About Efgartigimod
Efgartigimod is a phase 2 stage product being developed by Argenx for Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT05918978. Target conditions include Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04777734 | Pre-clinical | Completed |
| NCT07011589 | Phase 1/2 | Recruiting |
| NCT06860633 | Approved | Recruiting |
| NCT06298565 | Pre-clinical | Recruiting |
| NCT06299748 | Pre-clinical | Recruiting |
| NCT06203457 | Phase 2 | Completed |
| NCT05918978 | Phase 2 | Terminated |
| NCT04274452 | Phase 3 | Withdrawn |
| NCT04225156 | Phase 3 | Completed |
| NCT04188379 | Phase 3 | Completed |
Competing Products
6 competing products in Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abrocitinib + Placebo | Pfizer | Phase 2 | 51 |
| Nirmatrelvir/ritonavir + Placebo/ritonavir | Pfizer | Phase 2 | 51 |
| IgPro20 + Placebo | CSL | Phase 3 | 76 |
| Vericiguat Oral Tablet | Bayer | Phase 2 | 49 |
| Meplazumab for injection | Pacific Biosciences | Phase 3 | 69 |
| Vortioxetine + Placebo | Brain Biotech | Phase 2 | 44 |